Peter Lawson
Stock Analyst at Barclays
(1.49)
# 3,522
Out of 5,129 analysts
101
Total ratings
42.05%
Success rate
-10.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $385 → $394 | $351.27 | +12.16% | 2 | Feb 4, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $21.71 | +1.34% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $98.84 | +2.19% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $31.90 | +25.39% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $11.98 | +108.68% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $7.76 | -61.34% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $42.94 | -6.85% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.72 | +74.42% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.17 | +70.94% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $7.37 | +35.69% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.60 | +53.85% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $12.22 | -50.90% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $32.97 | +57.74% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $7.84 | +40.31% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $13.09 | +22.23% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $5.53 | +171.49% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $21.36 | -34.46% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.31 | +129.01% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $0.97 | +208.52% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.61 | +148.45% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $97.99 | -38.77% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $9.15 | +85.79% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $16.11 | +92.43% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $12.61 | +3.09% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.09 | +139.23% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $5.56 | -37.05% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $116.38 | +213.63% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.71 | +66.01% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $66.35 | +578.22% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $1.77 | +2,442.37% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $48.32 | -6.87% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Feb 4, 2026
Maintains: Overweight
Price Target: $385 → $394
Current: $351.27
Upside: +12.16%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $21.71
Upside: +1.34%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $98.84
Upside: +2.19%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $31.90
Upside: +25.39%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $11.98
Upside: +108.68%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $7.76
Upside: -61.34%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $42.94
Upside: -6.85%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.72
Upside: +74.42%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.17
Upside: +70.94%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $7.37
Upside: +35.69%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.60
Upside: +53.85%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $12.22
Upside: -50.90%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $32.97
Upside: +57.74%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $7.84
Upside: +40.31%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $13.09
Upside: +22.23%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $5.53
Upside: +171.49%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $21.36
Upside: -34.46%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.31
Upside: +129.01%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $0.97
Upside: +208.52%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.61
Upside: +148.45%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $97.99
Upside: -38.77%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $9.15
Upside: +85.79%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $16.11
Upside: +92.43%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $12.61
Upside: +3.09%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.09
Upside: +139.23%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $5.56
Upside: -37.05%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $116.38
Upside: +213.63%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.71
Upside: +66.01%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $66.35
Upside: +578.22%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $1.77
Upside: +2,442.37%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $48.32
Upside: -6.87%